The approval represents the first major technological advance in CT in nearly a decade.
Just in time to commemorate the 50th anniversary of the first computed tomography (CT) scan, the US FDA announced it has granted 510(k) clearance to Siemens for its new NAEOTOM Alpha CT device, the first to utilize photon-counting.
The emergence of photon-counting detectors represents the next significant enhancement to CT use, allowing for more detailed information about the patient to be obtained while creating images with less information that is deemed not useful for review and analysis.
“About 15 years ago, work on photon-counting and its clinical vision started at Siemens Healthineers. We always believed in the tremendous clinical value and relentlessly worked on it together with our partners. We are excited that we have received FDA 510(k) clearance,” says André Hartung, Head of Diagnostic Imaging at Siemens Healthineers, in a statement.
By measuring each individual x-ray that passes through a patient’s body, photon-counting detectors can produce detailed three-dimensional images that can ultimately aid in making a diagnosis or treatment-related decisions.
“Computed tomography is an important medical imaging tool that can aid in diagnosing disease, trauma or abnormality; planning and guiding interventional or therapeutic procedures; and monitoring the effectiveness of certain therapies,” said Laurel Burk, Ph.D., assistant director of the Diagnostic X-ray Systems Team in the FDA’s Center for Devices and Radiological Health, in a statement. “Today’s action represents the first major new technology for computed tomography imaging in nearly a decade and underscores the FDA’s efforts to encourage innovation in areas of scientific and diagnostic progress.”
The technology ultimately processes x-rays differently; transforming the current two-step process in which X-rays are converted into visible light, which is then detected by a light sensor, into a single-step process in which X-ray photons are directly converted into digital electrical signals that are counted, ultimately producing an image with greater clarity and contrast.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
February 6th 2025The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.